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Abstract: The majority of ovarian cancer patients present with advanced disease and 
despite aggressive treatment, prognosis remains poor. Significant improvement in ovarian 
cancer survival will require the development of more effective molecularly targeted 
therapeutics. Commonly, mouse models are used for the in vivo assessment of potential 
new therapeutic targets in ovarian cancer. However, animal models are costly and time 
consuming. Other models, such as the chick embryo chorioallantoic membrane (CAM) 
assay, are therefore an attractive alternative. CAM assays have been widely used to study 
angiogenesis and tumor invasion of colorectal, prostate and brain cancers. However, there 
have been limited studies that have used CAM assays to assess ovarian cancer invasion and 
metastasis. We have therefore developed a CAM assay protocol to monitor the metastatic 
properties of ovarian cancer cells (OVCAR-3, SKOV-3 and OV-90) and to study the effect 
of potential therapeutic molecules in vivo. The results from the CAM assay are consistent 
with cancer cell motility and invasion observed in in vitro assays. Our results demonstrate 
that the CAM assay is a robust and cost effective model to study ovarian cancer cell 
metastasis. It is therefore a very useful in vivo model for screening of potential novel 
therapeutics. 
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1. Introduction 
Ovarian cancer is the most lethal gynecological malignancy. Most patients are diagnosed at an 
advanced stage when the cancer cells have already metastasized to the abdominal cavity. Ovarian 
cancer metastasis is characterized by the ability of ovarian cancer cells to detach from the ovary and to 
adhere and invade the peritoneal cell layer, which lines the organs in the abdominal cavity [1]. The 
development of new therapies with the aim to disrupt ovarian cancer metastasis requires the in vivo 
study of novel targets and molecules. However, commonly used murine models are costly and require 
a large number of animals as well as a long experimental time frame. An attractive alternative is the 
chick chorioallantoic membrane (CAM) assay. 
CAM assays have been widely used to study angiogenesis [2], tumor cell invasion and  
metastasis [3–6]. The CAM model has many advantages, such as (a) the highly vascularized nature of 
the CAM greatly promotes the efficiency of tumor cell grafting; (b) high reproducibility; (c) simplicity 
and cost effectiveness, and finally (d) as the CAM assay is a closed system, the half-life of many 
experimental molecules such as small peptides tends to be much longer in comparison to animal 
models, allowing experimental study of potential anti-metastatic compounds that are only available in 
small quantities [4,7]. The CAM is composed of a multilayer epithelium; the ectoderm at the air 
interface, mesoderm (or stroma) and endoderm at the interface with the allantoic sac [8]. Furthermore, 
the CAM contains extracellular matrix proteins (ECM) such as fibronectin, laminin, collagen type I 
and integrin ανβз [9]. The presence of these extracellular matrix proteins mimics the physiological 
cancer cell environment.  
Although the CAM assay is a well established model for studying tumour angiogenesis and 
invasion in malignancies such as bowel cancer [10,11], glioma [12–14], prostate cancer [15–17], 
leukemia [18] and osteosarcoma [19], there has only been one study to date that has used a CAM  
assay to assess ovarian cancer invasion and metastasis [20]. We recently investigated the ovarian  
cancer-peritoneal cell interaction and identified several novel proteins that may be involved in ovarian 
cancer metastasis [21,22]. To effectively determine their function, we developed a CAM assay 
protocol using a range of ovarian cancer cell lines to allow the monitoring of candidate molecules on 
ovarian cancer cell invasion in vivo. The in vivo CAM assay data was compared with results from  
in vitro assays.  
2. Results  
2.1. Human Ovarian Cancer Cell Motility and Invasion In Vitro 
We compared the motility and invasion of three ovarian cancer cells (OVCAR-3, SKOV-3 and  
OV-90) using in vitro assays. We found OV-90 cells to be most invasive through an extracellular 
matrix and migrated faster through 12 µm pores towards a chemo attractant, compared to SKOV-3 and 
OVCAR-3 cells (Figure 1). OVCAR-3 cells were the least motile and invasive cell line in our study. 
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Figure 1. Motility and invasion of human ovarian cancer cell lines (OVCAR-3, SKOV-3 
and OV-90) in vitro. The fluorescence reading represents the cancer cells that have 
migrated through the pores or invaded through the extracellular matrix (Geltrex). Data 
represents the mean ± SEM from two independent experiments performed in quadruplicate. 
(a) Indicates significant difference from OVCAR-3 cells; and (b) indicates significant 
difference from SKOV-3 cells, p < 0.05.  
 
2.2. Human Ovarian Cancer Cell Invasion into the Chick Chorioallantoic Membrane (CAM) 
We initially utilized an ex ovo method and incubated the chick embryos in plastic weigh boats as 
described previously [23]. The ex ovo method has the advantage of allowing the application of a larger 
number of matrigel grafts as a wider area of the CAM is accessible. However, the survival rate for the 
ex ovo method was very low and only 10% of embryos survived to day 14. The in ovo method had a 
survival rate of 70% on day 14. In the in ovo method, a small window is made in the shell on day 3 of 
chick embryo development to detach the CAM layer from the egg shell (Figure 2a). Ovarian cancer 
cells (9 × 105 cells) were mixed with matrigel to form a gel and grafted on top of the CAM of day 11 
chick embryos. The chick embryos were incubated with the matrigel grafts until day 14 of 
development. An example of a matrigel graft on day 14 is shown in Figure 2b.  
Figure 2. (a) Day 3 chick embryo; (b) Ovarian cancer cells and matrigel graft on the chick 
chorioallantoic membrane (CAM) on day 14.  
 
The CAM layers; ectoderm (ET), mesoderm (M) and endoderm (ED) can be seen in Figure 3a. 
Cytokeratin immunohistochemistry was used to identify the CAM layer integrity and presence of 
ovarian cancer cells in the mesodermal layer.  
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Figure 3. Invasion of ovarian cancer cells in the chick chorioallantoic membrane (CAM). 
(a) Control showing the normal structure of the CAM layers; ectoderm (ET),  
mesoderm (M) and endoderm (ED); (b) OVCAR-3; (c) SKOV-3; and (d) OV-90 cancer 
cell matrigel grafts (CM) were placed on top of the ectoderm layer and cancer cell invasion 
into the CAM mesoderm was assessed in day 14 chick embryos. CAM paraffin sections  
(6 µm) were immunostained with cytokeratin antibody. Original magnification ×200, scale 
bar 100 µm.  
 
The invasion of the ovarian cancer cells through the ectoderm into the mesoderm was assessed on 
day 14 of chick embryo development. OVCAR-3 cytokeratin immunohistochemistry showed some 
damage to the ectoderm layer but minimal invasion into the CAM mesoderm (Figure 3b). The SKOV-3 
cells showed invasion into the mesoderm layer and minimal destruction of the ectoderm layer (Figure 3c). 
OV-90 cells were the most invasive cells in the CAM assay (Figure 3d), which agrees with the results 
of the in vitro assays (Figure 1). Figure 3d shows a large number of OV-90 cells invading into the 
mesoderm of the CAM, as well as the destruction of the CAM ectoderm layer.  
Quantitative analysis of ovarian cancer cell invasion into the CAM was performed by determining 
the number of images (8 to 12 sections per chick embryo) with cancer cell invasion into the CAM 
mesoderm of day 14 chick embryos. Our results showed a significantly higher invasion of OV-90 and 
SKOV-3 cells into the CAM mesoderm, when compared with OVCAR-3 cells (Figure 4).  
2.3. The Effects of Protein a Neutralizing Antibody on OV-90 Cancer Cell Invasion into the CAM 
We used a neutralizing antibody against one of the novel proteins identified in our previous study 
investigating ovarian cancer-peritoneal cell interactions [21,22]. OV-90 cancer cells  
(9 × 105 cells) were mixed with matrigel and the control anti-mouse IgG or the neutralizing antibody 
against protein A before grafting onto day 11 chick embryos. Neutralizing antibody against protein A 
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effectively inhibited OV-90 cancer cell invasion into the mesoderm of the CAM, compared with the 
control anti-mouse IgG, where OV-90 cancer cells invaded the mesoderm of the CAM and a 
destruction of the ectoderm layer was observed (Figure 5).  
Figure 4. Chick chorioallantoic membrane (CAM) invasion by ovarian cancer cells in day 
14 chick embryos. Data generated from 48–60 images from 6 chicken embryos per cell 
line. Data represents the percentage of images with invasion into the mesoderm,  
mean ± SEM from two independent experiments. (a) Indicates significant difference from 
OVCAR-3 cells; and (b) indicates significant difference from SKOV-3 cells, p < 0.05.  
 
Figure 5. Effects of protein A neutralizing antibody on OV-90 cancer cell invasion into the 
chick chorioallantoic membrane (CAM). OV-90 cancer cells were mixed with matrigel and 
(a) control anti-mouse IgG (20 µg/mL); or (b) neutralizing antibody against protein A  
(20 µg/mL). CAM paraffin sections (6 µm) were immunostained with a pan-cytokeratin 
antibody. ET = ectoderm. M = mesoderm. ED = endoderm. CM = cancer cell matrigel 
grafts. Original magnification ×200, scale bar 100 µm.  
 
3. Discussion  
The CAM assay is a frequently applied model to study ovarian cancer angiogenesis [24–27]. 
However, there is only one study which has used CAM assays to assess ovarian cancer cell invasion 
and metastasis [20]. Chang et al. described IGROV-1 ovarian cancer cell invasion and metastasis to 
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the posterior CAM and lungs of chick embryos [20]. We have developed a CAM assay protocol to 
monitor the metastatic properties of ovarian cancer cells (OVCAR-3, SKOV-3 and OV-90) and have 
successfully used it to study the effect of newly identified molecules in vivo. Our results show that the 
CAM assay is an effective model to study ovarian cancer metastasis. Importantly, our CAM model 
closely mimics the mode of ovarian cancer metastasis which involves ovarian cancer cell attachment 
and invasion into the peritoneum. The ectodermal layer of the CAM has many similarities with  
the peritoneum, which consists of a single layer of mesothelial cells covering the organs in the  
abdominal cavity. 
We observed a higher survival rate with the in ovo method in comparison to the ex ovo method for 
monitoring of ovarian cancer cell growth in the chick embryos. Various methods have been used to 
graft cancer cells in the CAM model; such as collagen onplants [23], plastic rings [19], and matrigel 
grafts [28]. Furthermore, cancer cells can also be inoculated by dropping the cell suspension on top  
of the CAM [29], or administered intravenously to study metastasis of cancer cells in the chick  
embryos [18]. Matrigel is one of the most suitable scaffolds used for implantation and grafting of 
cancer cells onto the CAM. In our model, ovarian cancer cells and matrigel were mixed with or 
without neutralizing antibodies before grafting onto the CAM of the chick embryos to assess ovarian 
cancer cell invasion. The grafting of the matrigel in the CAM model allows continuous visualization of 
the test site. Moreover, other studies have reported visible and solid tumors on the CAM of chick 
embryos a few days after cancer cell inoculation [11,19]. We used histological assessment by means of 
a pan-cytokeratin antibody, to allow the visualization of cancer cells invading into the mesoderm.  
The CAM model has been previously employed to assess cancer metastasis [3,29]. In some studies 
quantitative alu PCR was used to assess the presence of metastatic human cancer cells in chick embryo  
organs [30]. Several studies have compared both CAM assays and mouse models to assess tumor 
growth and metastasis. Colorectal cancer cells were reported to colonize the CAM similarly to  
the mouse model [10]. Strojnik et al. conducted a study to compare the histological and 
immunohistochemical characteristics of glioma tumor protein expression in the CAM and an 
established rat model. They reported a similar profile of proteins expressed in both models [12].  
In addition, the CAM model has also been used concurrently with the nude mice model to assess tumor 
growth of fibrosarcoma (HT1080 cells) and human squamous carcinoma (Hep3 cells) cells [31].  
Lyu et al. also showed that over expression of urokinase-type plasminogen activator receptor (u-PAR) 
in Hep3 cells leads to an increase in cancer cell invasion in the CAM model as well as accelerated 
tumor growth in the SCID mice model [32]. These studies demonstrate the validity of the CAM model 
for in vivo analysis of cancer cell invasion and metastasis. 
The CAM model has many advantages. It is cost effective, allows large scale screening and is an 
easily reproducible in vivo model [4,7]. A comparison of the advantages and limitations of the CAM 
against the mouse model are summarized in Table 1.  
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Table 1. Comparison of the advantages and limitations of the chick chorioallantoic 
membrane (CAM) and mouse model. 
In vivo 
model 
Advantages Reference Limitations Reference 
CAM 
Short experimental assay (days)  Short observation period (days)  
Inexpensive  
Cannot examine cancer-immune  
cell interactions 
 
Easily reproducible and high throughput  Rapid morphological changes [4] 
Closed system—allows assessment of 
small quantities of therapeutic agents 
 
Limited antibodies to chicken tissues  
for characterization 
[7] 
Naturally immunodeficient [7] 
 
Multiple tests per individual CAM 
[4] Allows large scale screening 
Biology and physiology well known 
Availability of in vivo imaging [3] 
Allows direct visualization 
[8] 
Animals do not have to be restrained 




Longer observation period (weeks to 
months) 
 
Long experimental length (months to 
years) 
[4] 
Biology and physiology well known,  
but also complex 
[4] Costly 
Availability of in vivo imaging [33] Mature immune system 
Defined genetic background [34] Reproducibility is expensive 
 
Large number of animals required 
Animals have to be restrained [8] 
The CAM model has also been used in pre-clinical screening to assess the efficacy of drugs and 
inhibitors on tumor growth. Hagedorn et al. reported that treatment of human glioma cells with 
receptor tyrosine kinase inhibitors inhibited tumor growth in a CAM model [14]. Bekes et al., 
demonstrated that treatment of prostate cancer (PC3 cells) with u-PA activation blocking antibody 
mAb-112 significantly inhibited cancer cell invasion in the CAM model [35]. Additionally, the CAM 
model has been used to test the efficacy of chemotherapy agents (such as doxorubicin) in human 
leukemia cell lines and has been shown to reduce cancer cell growth in the CAM [18]. An important 
limitation of the CAM model is the inability to assess cancer–immune cell interactions. Examination of 
cancer–immune cell interactions requires the use of transgenic ovarian cancer models [36], however, 
these models are not widely available, are not suitable for high throughput screening, and cannot be 
used with primary ovarian cancer cells derived from clinical samples. The CAM assay is therefore an 
attractive model to rapidly assess the effectiveness of novel candidate therapeutic drugs and the in vivo 
inhibition of specific tumor types and subtypes in one consistent model.  
We have shown that OV-90 ovarian cancer cells invade into the mesoderm of the CAM within three 
days of implantation, therefore making the OV-90 CAM model ideal for studying ovarian cancer 
invasion and metastasis. In contrast, the OVCAR-3 cells showed limited invasion in the CAM over the 
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three days of our assays, and would therefore be suitable for studying the role of molecules that 
promote ovarian cancer invasion. In conclusion, the CAM model provides a high throughput in vivo 
model for the assessment and evaluation of candidate pro-invasive molecules as well as potential 
therapeutic targets for ovarian cancer. 
4. Materials and Methods  
4.1. Cell Culture 
The human ovarian cancer cell lines OVCAR-3, SKOV-3 and OV-90 were obtained from American 
Type Culture Collection (ATCC, Manassas, VA, USA). All ovarian cancer cell lines were maintained 
in RPMI 1640 medium supplemented with 4 mM L-glutamine, antibiotics (100 U penicillin G,  
100 µg/mL streptomycin sulfate and 0.25 µg/mL amphotericin B), (Sigma-Aldrich, St. Louis, MO, 
USA). OVCAR-3 and SKOV-3 cells were supplemented with 5% fetal bovine serum (FBS)  
(Sigma-Aldrich) and OV-90 cells were supplemented with 10% FBS. All cell lines were maintained at 
37 °C in an environment of 5% CO2.  
4.2. Cell Motility and Invasion Assays 
Cell motility and invasion assays were performed as previously described [37]. Briefly, the ovarian 
cancer cells (OVCAR-3, SKOV-3 and OV-90) were diluted to a cell concentration of 1 × 106 cells/mL 
and labeled with calcein-AM (1 µg/mL, Life Technologies, VIC, Australia). Ovarian cancer cells were 
mixed at room temperature for 1 hour in the dark on an oscillating platform. Ovarian cancer cells  
(50 µL, 40,000 cells) were loaded on top of uncoated 12 µm filter inserts (Disposable, 96-well plate, 
ChemoTx, Neuro Probe Inc, Gaitherburg, MD, USA) for motility assays or 12 µm filters coated with 
Geltrex (0.6 µL/well, 9 mg/mL, Life Technologies) for invasion assays. 10% FBS RPMI media was 
used as a chemo attractant. The cells were allowed to migrate and invade to the lower chamber for  
6 hours. Non-migratory cells on the top of the filter were removed and the fluorescence was measured 
at 485–520 nm.  
4.3. Chick Chorioallantoic Membrane Assay (CAM Assay) 
Fertilized white leghorn chicken eggs were obtained from Hi-Chick, South Australia, Australia. 
Eggs were incubated in a MultiQuip Incubator (E2) at 37 °C with 60% humidity. Ethics approval was 
obtained by the University of Adelaide Animal Ethics Committee. A small window was made in the 
shell on day 3 of chick embryo development under aseptic conditions. The window was resealed with 
adhesive tape and eggs were returned to the incubator until day 11 of chick embryo development.  
On day 11, OVCAR-3, SKOV-3 and OV-90 cell suspensions (9 × 105) were mixed with growth factor 
reduced matrigel (8.9 mg/mL, BD Biosciences, NSW, Australia) in a total volume of 30 µL. Control 
anti-mouse IgG (20 µg/mL) (Sigma Aldrich) and neutralizing antibody to protein A (20 µg/mL) (BD 
Biosciences) were mixed together with the OV-90 cancer cells and matrigel. Matrigel grafts were 
placed on top of the CAM and eggs were resealed and returned to the incubator for 72 hours until day 
14 (n = 6 chicken embryos per cell line). Matrigel grafts with surrounding CAM were harvested from 
each embryo and fixed with 4% paraformaldehyde for 24 hours and embedded in paraffin. Serial 
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sections (6 µm) were stained with hematoxylin and eosin. Slides were digitally scanned using the 
NanoZoomer (Hamamatsu Photonics K.K., Japan).  
4.4. Immunohistochemistry 
CAM paraffin sections (6 µm) were incubated on a heat plate at 60 °C for 2 hours. Tissue sections 
were dewaxed with xylene and ethanol, followed by PBS washes. Antigen retrieval was performed by 
using 1% protease (Sigma-Aldrich) for 10 minutes on a heat plate at 37 °C. The endogenous 
peroxidase activity of the sections was quenched with 0.3% H2O2. Each tissue sample was blocked 
with 5% goat serum for 30 minutes before incubation with monoclonal mouse anti-human cytokeratin 
clone AE1/AE3 (1:50, Dako, VIC, Australia) at 4 °C overnight. Subsequently, the tissues sections 
were incubated sequentially with biotinylated goat anti-mouse (1:400, Dako), followed by  
streptavidin-HRP conjugated (1:500, Dako) for 1 hour at room temperature. Immunoreactivity was 
detected using diaminobenzidine/H2O2 substrate (Sigma-Aldrich). The sections were counterstained 
with 10% haematoxylin (Sigma-Aldrich), dehydrated and mounted in Pertex (Medite Medizintechnik, 
Germany). Slides were digitally scanned using the NanoZoomer (Hamamatsu Photonics K.K.). For 
quantitative analysis of ovarian cancer cell invasion into the mesoderm layer, 8 to 12 CAM images 
from each embryo were assessed by two independent researchers [16]. 
4.5. Statistical Analysis 
All analyses were performed using SPSS 15.0 for Windows software (SPSS, Chicago, IL, USA). 
The student’s t-test and one-way ANOVA were used to determine statistical significance of ovarian 
cancer cell motility and invasion in vitro, and ovarian cancer cell invasion in the CAM model. 
Statistical significance was accepted at p < 0.05. 
5. Conclusions  
The CAM assay is a robust technique that can be used to monitor invasion of ovarian cancer cell 
lines and to assess the role of novel molecules and potential therapeutic targets. It is a valuable 
alternative to murine in vivo models for the study of ovarian cancer invasion and metastasis. 
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